Current and future biomarkers in XXXX .

@entity32 @entity2023 @entity565 @entity1198 @entity56 @entity25541 @entity1096
UNASSIGNED: Diagnosis early in life, sensitization, @entity565 endotypes, monitoring of disease and treatment progression are key motivations for the exploration of biomarkers for @entity2023 and @entity56 . The number of genes related to @entity2023 and @entity56 increases steadily, however prognostic genes have not yet entered clinical application. We hypothesize that the combination of multiple genes may generate biomarkers with prognostic potential. The current review attempts to group more than 161 different potential biomarkers involved in @entity32 to pave the way for future classifiers. The potential biomarkers are categorized into either epithelial or infiltrate-derived or mixed origin, epithelial biomarkers. Furthermore surface markers were grouped into cell-type specific categories. The current literature provides multiple biomarkers for potential @entity565 endotypes that are related to T cell phenotypes such as @entity1198 , Th2, Th9, Th17, Th22 and Tregs and their lead cytokines. Eosinophilic and @entity565 endotypes are also classified by epithelium-derived @entity25541 and @entity1096 , respectively. There are currently about 20 epithelium-derived biomarkers exclusively derived from epithelium, which are likely to innovate biomarker panels as they are easy to sample. This article systematically reviews and categorizes genes and collects current evidence that may promote these biomarkers to become part of @entity2023 or @entity56 classifiers with high prognostic value. This article is protected by copyright. All rights reserved.
